| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 431.310 | 448.464 | 424.288 | 398.350 | 411.504 | 394.972 | 337.415 | 339.750 | 359.635 | 356.502 |
| Total Income - EUR | 432.990 | 449.763 | 425.218 | 398.805 | 412.360 | 395.481 | 337.480 | 343.295 | 365.550 | 362.946 |
| Total Expenses - EUR | 428.608 | 463.732 | 435.682 | 394.796 | 391.231 | 371.121 | 326.618 | 332.571 | 352.363 | 364.641 |
| Gross Profit/Loss - EUR | 4.382 | -13.968 | -10.464 | 4.010 | 21.129 | 24.361 | 10.862 | 10.725 | 13.186 | -1.695 |
| Net Profit/Loss - EUR | 2.735 | -13.968 | -15.138 | 21 | 17.006 | 20.710 | 7.723 | 7.361 | 9.859 | -11.284 |
| Employees | 7 | 7 | 6 | 5 | 5 | 4 | 4 | 4 | 4 | 4 |
Check the financial reports for the company - Iatrofarm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 61.912 | 81.547 | 61.666 | 56.060 | 47.133 | 45.415 | 44.317 | 43.139 | 41.711 | 106.065 |
| Current Assets | 182.942 | 147.967 | 122.255 | 126.463 | 124.428 | 125.762 | 108.175 | 108.237 | 118.715 | 91.438 |
| Inventories | 69.340 | 68.607 | 61.982 | 46.745 | 60.001 | 55.492 | 53.190 | 58.355 | 64.890 | 57.788 |
| Receivables | 38.476 | 17.446 | 44.068 | 69.490 | 40.651 | 47.476 | 32.353 | 38.311 | 30.893 | 17.812 |
| Cash | 75.125 | 61.914 | 16.206 | 10.228 | 23.775 | 22.794 | 22.632 | 11.570 | 22.931 | 15.839 |
| Shareholders Funds | 164.726 | 134.866 | 108.348 | 104.017 | 90.426 | 109.422 | 94.503 | 92.018 | 101.598 | 87.133 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 79.643 | 94.648 | 75.102 | 78.043 | 80.681 | 61.310 | 57.553 | 58.921 | 58.392 | 109.938 |
| Income in Advance | 484 | 479 | 471 | 463 | 454 | 445 | 435 | 437 | 435 | 433 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Iatrofarm Srl